Biomarker Type: Proteomic
-
Assessing a biomarker’s ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting
-
Budget Impact of a Blood-Based Integrated Classifier Test to Reclassify Risk of Pulmonary Nodules in a US Commercial Payer Setting
-
Budget Impact of a Blood-Based Integrated Classifier Test to Down Classify Riskof Pulmonary Nodules in a US Medicare Payer Setting
-
Shifting the Intervention Probability Curve for Lung Cancer Diagnosis Following Biomarker Implementation: A Novel Clinical Endpoint for Biomarker Clinical Trials
-
Real-world demographics, baseline characteristics, healthcare resource utilization and costs amongst non-small cell lung cancer (NSCLC) patients tested with a Host Immune Classifier (HIC)
-
Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results from the INSIGHT Registry Study
-
Comparison Of The Performance Of A Blood-Based Integrated Classifier In Risk Stratifying Incidental And Screening-Detected Pulmonary Nodules
-
Impact Of A Blood-Based Integrated Classifier To reclassify Lung Nodule Risk Across Nodule Size spectrum